Wire · opportunities
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
Bristol Myers Squibb reported interim Phase 1 results from the Breakfree-2 study showing promising safety and efficacy of zolacabtagene autoleucel, a CD19-directed CAR T cell therapy, in patients with highly active relapsing and progressive multiple sclerosis. The treatment demonstrated potential for immune reset, with most patients remaining off disease-modifying therapies and showing stability or improvement in disease progression.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You can target autoimmune diseases with CAR T therapies that reset the immune system and reduce drug dependence. Development and trial success here pre-empt a shift in how neurological autoimmune disorders get treated.
◆ Coverage
1 source · 23 Oct 2026
◆ Related on Wire
◆ Topics